ESG

Affluent travelers are spending more but seeking meaning over opulence. A new report shows how wellness, advisors, and payments are shaping travel's future.

Omeros begins sales of YARTEMLEA, the first and only approved therapy for TA-TMA, a fatal complication of stem cell transplants, shifting the paradigm.

After renewing a $175M credit facility, Better.com reaffirms its ambitious goal of profitability, leaning on AI and new partnerships to fuel its comeback.

Myriad Genetics is launching a new cancer test that promises to detect recurrence earlier than ever. But can it win in a competitive market?

MHC's new 'accessibility-by-design' approach embeds compliance into documents before creation, aiming to end costly remediation and improve CX.

A tech startup’s AI has published more new scent patents than all major fragrance houses combined, signaling a massive disruption for the perfume industry.

A new partnership will validate Obagi's first FDA-approved filler using real-world data across a national network, signaling a shift in the industry.

As autonomous AI agents enter the workplace, Fiddler AI has raised $30M to build a critical 'control plane' for managing their risks and ensuring safety.

A new partnership aims to integrate advanced battery tech and custom controls, accelerating the shift to zero-emission machinery in demanding sectors.

A new framework signals a major shift from message control to radical transparency. Here's why brands that embrace authenticity will win in a skeptical market.

ENNOVI's Tijuana expansion offers a key nearshoring solution for medical device makers, tackling complex regulations and streamlining North American supply chains.

BioTalent Canada's latest awards highlight how inclusivity, diversity, and equity are becoming key drivers of innovation and profit in the bioscience sector.

New research provides the strongest human evidence that sleep actively clears toxic proteins linked to Alzheimer's, opening a new frontier for prevention.

A Norwegian firm's new AI software aims to reduce physician distractions and build trust, setting a new standard for cancer-detecting technology.

Veteran leader Emma Rooth takes charge at PCCA UK, bringing a track record of transformation to the booming personalized medicine market.

A new report reveals 84% of high-risk firms are unprepared for insider threats as state actors increasingly target the human factor within organizations.

With drug pipelines facing staggering failure rates, HKeyBio's new preclinical strategy aims to de-risk R&D and accelerate effective new treatments.

LuskinOIC honors a pioneer of artificial joints with a new award, celebrating a legacy of innovation and propelling the next wave of orthopaedic discovery.

A French biotech is advancing a novel class of drugs that don't just fight cravings but may reverse the deep-seated brain changes caused by addiction.

As AI attacks target meaning, not just code, NeuralTrust and academic partners propose the Generative Application Firewall to secure the next wave of apps.